Skip to main content
An official website of the United States government
Email

Documents and Memos for CTEP-Supported Trials

Clinical researcher holding a tablet

CTEP’s memos and guidelines are intended to ensure patient safety while providing the National Cancer Program with the most effective new agent development program possible. Some documents reflect the regulatory requirements of the Food and Drug Administration (FDA) and the Department of Health and Human Services (DHHS). Others have been developed based on policies at the Institute level, consensus among CTEP staff, NCI advisory boards, and leaders in the community of clinical investigators. Specific memos and procedures continue to evolve; through them CTEP, DCTD, NCI aims to provide a flexible, responsive system within the constraints imposed by regulation and the program’s size and scope.

Trial Conduct

Lead Organizations: Protocol Design and Conduct

Broadening Eligibility Criteria

Slow Accrual Guidelines

Other LPO Topics

CTEP Program Guidelines and Policies

NCTN

ETCTN

Memo Archive

Guidance for clinical trials affected by novel coronavirus (2020)

Other Archived Memos

  • Updated:

If you would like to reproduce some or all of this content, see Reuse of NCI Information for guidance about copyright and permissions. In the case of permitted digital reproduction, please credit the National Cancer Institute as the source and link to the original NCI product using the original product's title; e.g., “Documents and Memos for CTEP-Supported Trials was originally published by the National Cancer Institute.”

Email